CAPLIN POINT LABORATORIES LTD. - 524742 - Outcome Of Board Meeting
Outcome of Board Meeting06-05-2021
06-05-2021
Caplin Point Laboratories Ltd - 524742 - Board to consider FY21 Results & Interim Dividend on May 06, 2021
Caplin Point Laboratories Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 06, 2021, inter alia, to consider and approve :1. the annual audited financial results of the Company for the year ended March 31, 2021 (both standalone & consolidated) and2. declaration of Interim Dividend, if any, for the FY 2020-21 and fixation of record date for determining the eligibility of shareholders.As informed earlier vide the Company's letter dated March 30, 2021, the trading window for dealing in the Company's scrips by the Directors and Designated Employees of the Company will remain closed from April 01, 2021 to May 08, 021 (both days inclusive), in terms of the Company's Code of Conduct to regulate, monitor and report trading by insiders, read with SEBI (Prohibition of Insider Trading) Regulations, 2015.30-04-2021
CAPLIN POINT LABORATORIES LTD. - 524742 - Board Meeting Intimation for Board Meeting Intimation
CAPLIN POINT LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/05/2021 ,inter alia, to consider and approve i) the annual audited financial results of the Company for the year ended 31st March 2021 (both standalone & consolidated) and ii) declaration of Interim Dividend, if any, for the FY 2020-21 and fixation of record date for determining the eligibility of shareholders.30-04-2021
Caplin Point Laboratories Ltd - 524742 - Initial Disclosure To Be Made By An Entity Identified As A Large Corporate
Initial Disclosure to be made by an entity identified as a Large Corporate26-04-2021
CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Caplin Steriles gets USFDA approval for Prochlorperazine Edisylate Injection23-04-2021
Caplin Point Laboratories arm gets USFDA nod for Neostigmine Methylsulfate Injection
Neostigmine Methylsulfate Injection is a cholinesterase inhibitor and is indicated for the reversal of the effects of non-depolariSing neuromuscular blocking agents (NMBAs) after surgery.22-04-2021
CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Caplin Steriles gets USFDA approval for Neostigmine Methylsulfate Injection22-04-2021
Caplin Steriles gets USFDA nod for an heart injection
Caplin Steriles gets final nod for generic Milrinone Lactate injection, used for intravenous treatment of patients with acute decompensated heart failure.19-04-2021
Caplin Point Laboratories Ltd - 524742 - Shareholding for the Period Ended March 31, 2021
Caplin Point Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click here19-04-2021
CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Caplin Steriles Gets USFDA Approval for Milrinone lactate Injection19-04-2021